Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United States. The company is headquartered in Laguna Hills, California.
52W High
$2.42
52W Low
$0.80
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.24
Valuation
Attractive
As of 2025-07-31 (Overview)
Trailing P/E (<15 better)
0.30
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-12.02
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.12
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
10.64%
Institutions (25–75% balanced)
8.57%
Shares Outstanding
6,863,700
Float
6,072,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-07-31 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
3.19
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
0.67%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
0.0230
Previous
0.0209
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025